MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-03-2026
Evolus EPS Ratio 2011-2026 | EOLS
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Evolus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.8 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.27 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.27 | -4.83 | -1.69 |
Quarterly EPS Ratio Evolus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.24 | -0.27 | -0.3 | - | -0.3 | -0.18 | -0.22 | - | -0.3 | -0.32 | -0.26 | - | -0.36 | -0.42 | -0.31 | - | -0.35 | -0.31 | 0.17 | - | -0.34 | -0.63 | -0.59 | - | -0.98 | -1.37 | -0.4 | - | -0.48 | -0.69 | -0.3 | - | -0.16 | -0.14 | -0.24 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.17 | -1.37 | -0.381 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
-4.74 | $ 18.02 | - | $ 115 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M |  Irlanda |
 |
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | USA |
 |
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
-1.62 | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
-0.14 | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Aurora Cannabis
ACB
|
-4.1 | $ 3.43 | -1.44 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.05 | -3.67 % | $ 113 M | Canada |
 |
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-0.51 | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | USA |
 |
Relmada Therapeutics
RLMD
|
-1.45 | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Emergent BioSolutions
EBS
|
-14.8 | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Tilray
TLRY
|
-2.35 | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Pacira BioSciences
PCRX
|
-2.15 | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-1.1 | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-0.28 | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | USA |
 |
Viatris
VTRS
|
0.05 | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
-1.79 | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
SCYNEXIS
SCYX
|
-0.17 | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-1.99 | $ 8.02 | -0.99 % | $ 702 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 2.28 | -5.39 % | $ 2.83 M | USA |
 |
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-0.15 | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-0.74 | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
-0.05 | $ 2.07 | 0.98 % | $ 23.9 M | USA |